Lara Sullivan, Pyxis Oncology CEO
May 24, 2023 07:35 AM EDTUpdated 08:48 AM
Deals

Small SPAC to tiny sale: Apex­i­gen sprints to Pyx­is On­col­o­gy in $16M ex­it

Kyle LaHucik

Senior Reporter

Pyx­is On­col­o­gy, the pub­lic Boston biotech breath­ing life in­to Pfiz­er’s an­ti­body-drug con­ju­gates plat­form, will buy Apex­i­gen, a small on­col­o­gy out­fit …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times